Home/Filings/4/0001209191-08-067583
4//SEC Filing

KILLION FREDERICK 4

Accession 0001209191-08-067583

CIK 0000010081other

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 6:01 PM ET

Size

25.5 KB

Accession

0001209191-08-067583

Insider Transaction Report

Form 4
Period: 2008-12-23
KILLION FREDERICK
General Counsel
Transactions
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2315,0000 total
    Exercise: $49.49From: 2008-11-11Exp: 2017-03-07Common Stock (15,000 underlying)
  • Disposition to Issuer

    Common Stock

    2008-12-2311,5890 total
  • Disposition to Issuer

    Stock Options

    2008-12-2330,0000 total
    Exercise: $35.01Exp: 2014-08-04Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Options

    2008-12-2362,5000 total
    Exercise: $30.19Exp: 2012-03-01Common Stock (62,500 underlying)
  • Disposition to Issuer

    Stock Options

    2008-12-2345,0000 total
    Exercise: $43.34Exp: 2013-07-30Common Stock (45,000 underlying)
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2330,0000 total
    Exercise: $46.99Exp: 2015-07-27Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Appreciation Rights

    2008-12-2345,0000 total
    Exercise: $49.22From: 2008-11-11Exp: 2018-03-04Common Stock (45,000 underlying)
Footnotes (10)
  • [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 7,268 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $462,401.10.
  • [F10]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $777,600, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
  • [F2]Option vested equally over a 3 year period from grant date
  • [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,269,581.25, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $30.1867 per share.
  • [F4]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,042,200, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share.
  • [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $944,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
  • [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $585,300, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
  • [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
  • [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,150, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
  • [F9]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share.

Issuer

BARR PHARMACEUTICALS INC

CIK 0000010081

Entity typeother

Related Parties

1
  • filerCIK 0001237261

Filing Metadata

Form type
4
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 6:01 PM ET
Size
25.5 KB